皮里迪尔-皮拉佐衍生物对Trypanosoma cruzi的活性
Denise da Gama Jaen Batista1, Ludmila Ferreira de Almeida Fiuza1, Frédérique Klupsch2
1Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, 210360-040, Brazil.
Experimental parasitology
|May 17, 2024
概括
新的候选药物显示出对治疗夏加斯病 (CD) 的前景. 研究人员确定了对Trypanosoma cruzi有效的有力阿里尔-皮拉佐衍生物,为改善现有选择之外的治疗提供了希望.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 查加斯病 (CD) 治疗依赖于过时的药物,如津醇 (Bz),这些药物具有包括副作用和在晚期疾病阶段有效性降低在内的局限性.
- 对于抗击Trypanosoma cruzi感染的新型,负担得起的治疗方法有着迫切的需要.
研究的目的:
- 评估一系列的阿里尔-皮拉佐衍生物对抗Trypanosoma cruzi的活性.
- 识别具有针对血液和细胞内寄生虫形式强烈活性的非细胞毒性化合物.
主要方法:
- 查基和基衍生物对T. cruzi. 的查.
- 在体外测试中使用血流三马斯蒂哥特和细胞内马斯蒂哥特形式.
- 细胞毒性和选择性指数的评估.
主要成果:
- 两种非细胞毒性皮里迪尔-皮拉佐衍生物在体内表现出强烈的活性,对抗细胞内T. cruzi,相当于本兹尼达.
- 一种化合物表现出明显高于本兹尼达对血流杆菌的活性,选择性指数>1000.
- 尽管试验室的结果很有希望,但由于血稳定性差,化合物在体内有效性有限.
结论:
- 阿里尔-皮拉佐隆衍生物代表了开发新的抗查加斯病药物的有前途的支架.
- 需要进一步优化以解决药物动力学限制,如血稳定性,以获得体内疗效.
- 这项研究提供了对新型抗试体药物设计策略的见解.
更多相关视频
06:13Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System
Published on: July 31, 2019
9.0K
08:48In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
3.3K
相关概念视频
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...